LGND Quote, Financials, Valuation and Earnings

Elanco Animal Health, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of -2.99%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Elanco Animal Health, Inc.'s return on equity of 0.55%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 24.31%. On the other hand Elanco Animal Health, Inc. has an analysts' consensus of $25.00 which suggests that it could grow by 10.62%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Elanco Animal Health, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Elanco Animal Health, Inc. has a beta of 1.859, suggesting its more volatile than the S&P 500 by 85.894%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elanco Animal Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Elanco Animal Health, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Elanco Animal Health, Inc. quarterly revenues of $1.1B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Elanco Animal Health, Inc.'s net income of -$34M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 94.25x while Elanco Animal Health, Inc.'s PE ratio is 310.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.34x versus 2.45x for Elanco Animal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 4.42%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 24.31%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $140.13 which suggests that it could grow by 46.77%. Given that Inspire Medical Systems, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Inspire Medical Systems, Inc. is more attractive than Ligand Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.412%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 94.25x while Inspire Medical Systems, Inc.'s PE ratio is 65.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.34x versus 3.25x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 21.47%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Johnson & Johnson's return on equity of 33.27%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 24.31%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 94.25x while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.34x versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 33.68%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 24.31%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.05%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 94.25x while Merck & Co., Inc.'s PE ratio is 14.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.34x versus 4.21x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.